首页> 中文期刊> 《癌症生物学与医学:英文版》 >Prognostic significance of combined fibrinogen concentration and neutrophil-to-lymphocyte ratio in patients with resectable non-small cell lung cancer

Prognostic significance of combined fibrinogen concentration and neutrophil-to-lymphocyte ratio in patients with resectable non-small cell lung cancer

         

摘要

Objective:Cancer-associated inflammation and coagulation cascades play vital roles in cancer progression and survival.In this study,we investigated the significance of the combination of preoperative fibrinogen and the neutrophil-to-lymphocyte ratio(NLR)in predicting the survival of patients with non-small cell lung cancer(NSCLC).Methods:We retrospectively enrolled 589 patients with NSCLC who underwent surgery.The univariate and multivariate Cox survival analyses were used to evaluate the prognostic indicators,including the combination of fibrinogen and NLR(F-NLR).The cut-off values for fibrinogen,NLR,and clinical laboratory variables were defined by the receiver operating characteristic(ROC)curve analysis.According to the ROC curve,the recommended cut-off values for fibrinogen and the NLR were 3.48 g/L and 2.30,respectively.Patients with both a high NLR(≥2.30)and hyperfibrinogenemia(≥3.48 g/L)were given a score of 2,whereas those with one or neither were scored as 1 or 0,respectively.Results:Our results showed that F-NLR was an independent prognostic indicator for disease-free survival(DFS)[hazard ratio(HR),1.466;95%confidence interval(CI),1.243–1.730;P<0.001]and overall survival(OS)(HR,1.512;95%CI,1.283–1.783;P<0.001).The five-year OS rates were 66.1%,53.5%,and 33.3%for the F-NLR=0,F-NLR=1,and F-NLR=2,respectively(P<0.001).Correspondingly,their five-year DFS rates were 62.2%,50.3%,and 30.4%,respectively(P<0.001).In the subgroup analyses of the pathological stages,the F-NLR level was significantly correlated with DFS and OS in stage I and IIIA cancers.Conclusions:Preoperative F-NLR score can be used as a valuable prognostic marker for patients with resectable early-stage NSCLC.

著录项

  • 来源
    《癌症生物学与医学:英文版》 |2018年第1期|P.88-96|共9页
  • 作者单位

    Department of Lung Cancer;

    Tianjin Medical University Cancer Institute and Hospital;

    National Clinical Research Center for Cancer;

    Key Laboratory of Cancer Prevention and Therapy;

    Ministry of Education;

    Tianjin’s Clinical Research Center for Cancer;

    Tianjin Lung Cancer Center;

    Department of Lung Cancer;

    Tianjin Medical University Cancer Institute and Hospital;

    National Clinical Research Center for Cancer;

    Key Laboratory of Cancer Prevention and Therapy;

    Ministry of Education;

    Tianjin’s Clinical Research Center for Cancer;

    Tianjin Lung Cancer Center;

    Department of Lung Cancer;

    Tianjin Medical University Cancer Institute and Hospital;

    National Clinical Research Center for Cancer;

    Key Laboratory of Cancer Prevention and Therapy;

    Ministry of Education;

    Tianjin’s Clinical Research Center for Cancer;

    Tianjin Lung Cancer Center;

    Department of Lung Cancer;

    Tianjin Medical University Cancer Institute and Hospital;

    National Clinical Research Center for Cancer;

    Key Laboratory of Cancer Prevention and Therapy;

    Ministry of Education;

    Tianjin’s Clinical Research Center for Cancer;

    Tianjin Lung Cancer Center;

    Department of Lung Cancer;

    Tianjin Medical University Cancer Institute and Hospital;

    National Clinical Research Center for Cancer;

    Key Laboratory of Cancer Prevention and Therapy;

    Ministry of Education;

    Tianjin’s Clinical Research Center for Cancer;

    Tianjin Lung Cancer Center;

  • 原文格式 PDF
  • 正文语种 CHI
  • 中图分类 肺肿瘤;
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号